Key facts
- Elevara Medicines’s last known valuation is $61.4M (Oct 2025).
- It has raised $70.3M; the latest was Early Stage VC ($70.3M) in Oct 2025.
- Notable investors include Sofinnova Partners, Forbion, Monograph Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Elevara Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Elevara Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elevara Medicines
Operator of a biotech company intended to transform rheumatoid arthritis treatment by targeting synovial fibroblasts to overcome limitations of current immunosuppressive therapies. The company offers a first-in-class oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes involved in RA pathobiology, enabling customers to achieve faster relief, improved remission rates and safer long-term outcomes.
- Sector
- Healthcare
- HQ
- Altrincham, United Kingdom
- Founded
- 2025
- Website
- elevara.com/
- Ownership
- Privately Held (backing)
Elevara Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elevara Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elevara Medicines in its N-PORT filings yet. We sweep new filings monthly.